Pipeline
Some good slogan. Some good slogan.
Timelines and milestones
ADA
- Status: Phase I concluded with positive results
BEA
- Status: commencing on 2 challenge studies and tox. batch manufacturing
- Next milestone: Entering clinical phase I
CARA
- Status: Commencing tox. batch manufacturing
- Next milestone: Entering clinical phase I
Timeline
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Combatting Antimicrobial Resistance and Diseases with High Unmet Medial Needs
Our OMV technology has demonstrated an excellent safety profile in a Phase I clinical trial, is administration route-agnostic, scalable and stable over years. See our diversified pipeline of high impact programs for more information.
Pipeline
ADA
Adjuvants are vital ingredients used in vaccinology for enhancing the strength and duration of immune protection. AdJane has developed its own adjuvants, ADA-24 for intramuscular administration and ADA-25 for intranasal administration, based on its proprietary OMV-Vacc platform technology. Unlike traditional adjuvants, ADA elicits both cellular (Th1), humoral (Th2), and mucosal (Th17) immune responses, resulting in stronger, more durable immunity. Our proprietary adjuvants are highly versatile and can be incorporated into bacterial or viral concepts, and produced in short timelines at high quality, following GMP requirements.
BEA
Gonorrhea is a major global public health concern and recognized as a priority pathogen by the WHO. It is one of the most common yet disruptive diseases worldwide, with nearly 100 million cases reported annually and potentially severe health consequences like infertility, neonatal blindness, and increased risk of HIV infection.
AdJane has developed BEA, a Gonorrhea vaccine based on its proprietary OMV-Vacc platform technology. The Neisseria Meningitidis bacteria – are designed to express Neisseria Gonorrhoeae antigens on their surface that are conserved among strains and/or important for growth, and capable of inducing bactericidal antibodies, thereby ensuring broad protection and strain coverage.
CARA
HFMD is one of the most common childhood diseases, particularly in Southeast Asia, the USA, and Australia. Despite the availability of several vaccines, infection rates and severe cases continue to rise due to limited strain coverage, leading to incomplete immunity, reinfections, and ongoing outbreaks. In severe cases, HFMD can cause neurological complications, respiratory issues, organ failure, and death.
AdJane has developed a next-generation multivalent HFMD vaccine that offers broad protection against four distinct strains. Unlike monovalent vaccines with limited coverage, it induces cross-protective immunity, significantly lowering the risk of outbreaks.